プログラム_指定演題.indd
|
|
|
- あきひろ おおかわち
- 5 years ago
- Views:
Transcription
1 400 Dementia Japan Vol. 27 No. 4 October : : β β Jorge A Ghiso Departments of Pathology and Psychiatry, New York University School of Medicine, New York, USA : : 18
2 : : : 1. Alzheimer Alzheimer AD ADNI AD AD Lewy DLB DLB Lewy DLB AGDSD - NFT AD : : 1. J - ADNI J - ADNI J - ADNI 19
3 402 Dementia Japan Vol. 27 No. 4 October J - ADNI PET 5. J - ADNI AD ADNeuroimaging Initiative ADNI J - ADNI 7 MCI 545 3,500 J - ADNI AD AD MCI AD J - ADNI2 AD : : Hsp40 4. Mechanism of disease progression in Lewy body diseases provides novel therapeutic opportunities. Department of Biomedical Science and Technology, Konkuk University, Seoul, Korea Seung - Jae Lee 30 seed 20
4 : : Charles Bonnet BPSD 18% 60% 10% 38% 5 IPA Complete Guide to BPSD, : :
5 404 Dementia Japan Vol. 27 No. 4 October 2013 AD amyloid β Aβ Aβ AD TREM2 1 AD 2 AD Aβ 3 4 NSAID : : 1. : 2. BPSD : 3. : AD 3 NMDA 4 AD BPSD : : 1. ; 2. 22
6 VCI - ND Vascular cognitive impairment - no dementia VCI 2011 AHA/ASA : : 1. ips : 4. ES in vitro in vivo : : 1. TDP
7 406 Dementia Japan Vol. 27 No. 4 October FTLD 3. FTD bvftd 4. PPA FTLD Frontotemporal lobar degeneration : FTLD Pick FTLD FTD bvftdrascovsky K, et al. SD PNFA Gorno - Tempini ML, et al, : :
8 : : : : PET 1980 FTDP ? 25
9 408 Dementia Japan Vol. 27 No. 4 October : : : : 1. β Solanezumab PMDA AD AD prodromal AD MCI due to AD preclinical AD 2 FDA Guidance for Industry, Alzheimer s disease : Developing drugs for the treatment of early stage disease, Draft guidance draft 24 AD AD : :
10 NPO : 1. Lewy 2. TDP - 43 FUS / TLS Ataxin 2 ALS / FTLD - U : : : : : : 27
11 410 Dementia Japan Vol. 27 No. 4 October : : : : : : : : : : : : : : : : : : : : : 28
12 : : Harald Hampel Professor of Neuroscience, Université Pierre et Marie Curie, L Institut de la Mémoire et de la Maladie : : : : : : : : : : : : : RI : 29
13 412 Dementia Japan Vol. 27 No. 4 October 2013 : F : F β 001 APP - Tg Aβ 002 Aβ 003 Aβ 004 CLAC Aβ 005 β 006 Aβ 007 γ p24α2 008 APPC 009 ips Aβ 010 β β Angiotensin type 1a receptor regulates amyloid plaque formation 013 Aβ 014 Aβ 30
14 413 β α Cross - seeding effects of amyloid β - protein and α - synuclein 017 β 018 Aβ 019 AD : Aβ 020 Αβ 021 ; J - ADNI 022 : 023 Multiple Antigenic Peptide MAP BAN50 SAS - ELISA p P HCNP 31
15 414 Dementia Japan Vol. 27 No. 4 October TREM2 036 hypocretin PET - CT 037 ALS/PDC 038 CADASIL SAM P Retromer Dynein TDP - 43 mrna 046 TERA/VCP/p97 DNA
16 APP PET PIB - PET posterior cortical atrophy PiB PET Logopenic Logopenic progressive aphasia J - ADNI 062 MS HDLS 063 Hereditary diffuse leukoencephalopathy with spheroids 064 HDLS 065 SPECT 066 HDLS : CSF1R 067 HDLS, NHD, CADASIL, CARASIL 33
17 416 Dementia Japan Vol. 27 No. 4 October PET/CT 069 DLB I - FP - CIT DLB Lewy 074 Lewy zonisamide 075 BPSD 076 DLB PD MOCA - J MMSE
18 R Corticobasal degeneration 089 preclinical PSP Voxel - BasedAnalysisMRI 091 FTLD - FUS 092 TDP AGD NBR co - morbidity ADL 101 MR - proadm 102 Mini Mental State Examination : RPLS
19 418 Dementia Japan Vol. 27 No. 4 October Notch3 CADASIL 107 Duchenne 108 inph 109 β Creutzfeldt - Jakob SPECT NHO F 11 C PiB 117 PiB - PET SUVR 118 MCI PET 119 PiB MCI APOE4 PiB J - ADNI PET F - Flutemetamol PET imaging 121 PiB PET β S 122 PET 36
20 F THK PET F THK C PBB3 PET 126 MCI AD 127 NAT MMSE, HDS - R, RBMT : Cardio - Ankle Vascular Index RCT 1 : RCT 2 : 137 AD8 138 : 139 microbleeds 140 : 1 - MRS 37
21 420 Dementia Japan Vol. 27 No. 4 October premci MRS VBM MR T 3.0T 3D MRI VBM 143 : VSRAD advance 144 VSRAD 145 MRI 146 amnestic MCI 147 fmri 148 Alzheimer : NVU Memantine NO MoCA - J 155 Memantine AD 156 BPSD 157 donepezil memantine 158 ADAS SPECT
22 CNS KNS study Alzheimer AChE 3 SPECT ADAS - Jcog SPECT 171 Withania somnifera β Solanezumab K Restless legs syndrome IVIg sink 39
23 422 Dementia Japan Vol. 27 No. 4 October : fmri AD 185 Alzheimer Parkinson QOL : MoCA - J ACE - R
24 FDG - PET BADS WCST Alzheimer 201 NAT : 208 VSRAD ezis 209 P MCI 41
25 424 Dementia Japan Vol. 27 No. 4 October NIRS BPSD : 224 BPSD Strategy 225 BPSD 226 BPSD Family Attitude Scale FAS
26 NHO : KN
27 426 Dementia Japan Vol. 27 No. 4 October
untitled
239 10 3 14 00 14 50 1 : 10 2 10 30 11 30 1 : 10 4 13 00 14 00 1 : 10 2 13 00 14 00 1 : Peter St. George - Hyslop University of Toronto 10 2 14 10 15 10 1 : Randall Bateman Neurology at Washington University
Diagnosis of Dementia: Update
10 C A 1 2 Normal SMI MCI Early Dementia B Moderate Dementia 3 Severe Dementia 4 5 D AD, VD, FTD, DLB, PDD Depression Dementia d/t GMC Modifiable risk factors and preventive factors for dementia 6-5 -
Systematic Review of Psychological Assessment for elder clients, No. The review about Intelligence or Memory Scale for Dementia Kyoko WATANABE
Systematic Review of Psychological Assessment for elder clients, No. The review about Intelligence or Memory Scale for Dementia Kyoko WATANABE http://www.stat. go.jp. % Mini Mental State Examination MMSE
56: Hands-on 4 Meet the Expert.
56:136 57 2016 28 5 18 21. 650-0046 6-9-1 650-0046 6-11-1 650-0046 6 10-1 2016 2 9 7 13 Hands-on 4 Meet the Expert. http://www.neurology-jp.org/sokaitiho/neuro2016/ 15,000 18,000 3,000 3,000 3,000 3,000
278 Dementia Japan Vol. 32 No. 3 September F BC : F : F : F :
23 277 10 13 15 00 16 00 1 1F : 10 12 8 50 9 40 1 1F : Peter J. Whitehouse Transdisciplinary Professor, Case Western Reserve University and University of Toronto 10 13 9 10 10 00 1 1F : George Perry Dean
Parkinson disease : ,
1 2012 7 24 Parkinson disease :10 50 100, 65 10 200 tremor rigidity (pill rolling) Cogwheel rigidity Akinesia Bradykinesia Resting tremor in Parkinson disease Parkinson disease: camptocormia Parkinson's
44-1(前11)7回春季大会
PET 5 18 5 20 5 18 5 20 5 18 5 20 5 18 5 20 5 18 17:10 18:35 19 5 18 20 URL: http://www.t-inform.co.jp/jsnm-s7/ 7 http://www.t-inform.co.jp/jsnm-s7/ 7 19 5 18 20 7 7 PET PET PET RI 2 19 PET PET PET 1
臨床神経学雑誌第48巻第9号
TDP-43 β Table1 Classificationofmotorneurondiseases(motorneurondiseaseofbroad sense) I I I IV ALS(motorneurondiseaseofnarrow sense) 1 SporadicALS Classictype Progressivebulbarpalsy(PBP)type Progressivemuscularatrophy(PMA)type
118 Dementia Japan Vol. 31 No. 1 January 2017 表 1. DLB に対して mect を行った先行研究 Rasmussen K 2003 USA Japan Japan Japan Japan 1 2
Dementia Japan 31 : 117-124, 2017 117 症例報告 要旨 1. はじめに 70 1 modified electroconvulsive therapy ; mect mect Modified electroconvulsive therapy in dementia with Lewy bodies with drug - resistant psychiatric
DementiaPhantomTestmanual
4 3 18 F FDG PET 4 PET 2018/10/31 1 3 2 3 2.1 PET(PET/CT)........................................... 3 2.2 ( )............................... 3 2.3.............................................. 3 3 3 3.1
Vol.21 No AD Japanese-ADNI J-ADNI 2015 AMED AD NA-ADNI 400 AD AD 2. NA-ADNI 研究の主な成果 NA-ADNI 2004 NA-ADNI ADNI, ADNI-GO ADNI-2 phase
アルツハイマー型認知症のバイオマーカーの現状と課題 Biochemical biomarkers for Alzheimer s disease: present status and awaiting solution 京都府立医科大学分子脳病態解析学 / 教授 * 1. はじめに 460 65 10 1 85 3 1 Alzheimer s disease AD 5 7 2500 AD 460
Vol.0 No. 0 図 Montreal Cognitive AssessmentMoCA orientation visuospatial attention orientation 4 visuospatial executive MMSE MoCA language language me
Parkinson 病の認知機能障害を MMSE と MoCA により評価した多施設共同研究 : 慶應 PD データベース Cognitive impairment in Parkinson s disease patients evaluated by the Montreal Cognitive Assessment and the Mini-Mental State Examination.
PET n = 7 AD n = 20 図 3 PiB AD A 3. わが国のアミロイド PET の現状 PET 100 PiB 15 BF 図 4 J-ADI 105 図 5 20%MCI 60% AD 90% MCI AD AD E ApoE 4 AD 4 図 6 4.
病態理解と薬剤開発におけるアミロイド PET 検査の現状 Current Status of Amyloid PET in Pathophysiological Research and Drug Development for Alzheimer s Disease 東京都健康長寿医療センター研究所附属診療所 / 所長 * 1. はじめに PET A A AD 図 1 AD AD PET 2. アミロイド
第６１巻５・６号（１２月号）／特集１頁目（本刷）
Special Issue 1Sudden cardiac death symposium in Tokushima Special Issue 2How to do for your health? Reviews Original Epidemiologic problems of sudden death of school children in Tokushima Prefecture
認知症治療薬の考え方，使い方
Ch a pterⅠ 1 はじめに わが国における高齢者の認知症有病率は今後も高くなり 認知症者が増 加していく可能性が示されている1,2 海外においても アジア アフリカ などを中心に今後の認知症者数が増大する可能性が指摘されている 一 方 欧米においては認知症者発症率の減少を指摘する報告もある しかし 高齢化もあって認知症者数は増加すると考えられ わが国のみならず世界 の認知症者数は増加すると考えられている
認知症診療ガイドライン2017_200_第2章.indd
2 behavioral and psychological symptoms of dementia BPSD BPSD BPSD 18 2 2 1,2 1 CQ 2 1 1. 2. frontotemporal lobar degeneration FTLD 3. 3 a. CQ 2 1 19 1 1 Alzheimer Lewy Alzheimer Alzheimer Lewy Alzheimer
Ⅰ診断 症候 鑑別診断 認知機能に関する訴え 正常ではなく認知症でもない 認知機能の低下あり 日常生活機能は正常 Amnestic n-amnestic 認知障害は記憶障害のみ 認知障害は１領域に限られる Amnestic Single 図1 表1 記憶障害 Amnestic Multiple n
1) 認知症 1 軽度認知障害 () とはどのような状態でしょうか? の診断基準を教えてください. 1 概要 Mild Cognitive Impairment() とは本来 Alzheimer 病 (AD) など認知症とはいえないが, 知的に正常ともいえない状態を指す. 最近ではおおよそ AD の前駆状態を意味する用語と捉える人が多い. このような状態が注目される背景には, 新治療薬開発により AD
がん診療におけるFDG FDG-PET/CTの役割
PET/CT PET/CT MRI PET PET/CT Kurashiki Central Hospital FDG-PET CT PET/CT (stage1) FDG-PET (stage1) PET/CT FDG-PET PET/CT (stage4) FDG-PET (stage4) PET/CT FDG-PET PET/CT PET/CT
606 Dementia Japan Vol. 29 No. 4 October 2015 Table 1. The day care for people with severe dementia Outline Subjects Personal distribution Medical man
Dementia Japan 29 : 605-614, 2015 605 原著 要旨 1. はじめに 1 26 4.2 80 2 3 A survey of daycare facilities for dementia people in Japan Tohmi Osaki, Kiyoshi Maeda 1 650-0017 7-5 - 2 Medical Center for Dementia,
認知症診療ガイドライン2017_800_第8章.indd
8CQ 8 frontotemporal lobar degeneration FTLD Pick Alzheimer FTLD Alzheimer FTLD frontotemporal dementia FTD FTLD FTLD FTLD behavioral variant frontotemporal dementia bvftd semantic dementia SD Sylvius
FTD off - label 79 FTD Boxer et al., 2012b Alzheimer s disease : AD Cholinesterase inhibitor : ChEI FTD FTD Mendez et al., 2007 FTD Kerssens et al., 2
78 Dementia Japan 29 : 78-85, 78 2015 原著 要旨 4 FTD 87 6 2 1/3 Off - label medication for frontotemporal dementia in Japan Shunichiro Shinagawa 1, Yusuke Yatabe 2, Kazue Shigenobu 3, Ryuji Fukuhara 2, Mamoru
11新里論文.indd
70 Dementia Japan 27 : 70-80, 2013 56 29 41 70 80.7±7.1 53% 70 HDS - R 14.3±6.4 80% Kazuhiro Niizato 1), Gen Ohi 2) 1) 156-0057 2-1 - 1 Department of Psychiatry, Tokyo Metropolitan Matsuzawa Hospital 2-1
<91E63989F182A482C295618A7789EF8FB4985E8F575F E696E6464>
1 4 1 13 1 4 6 7 2012 7 27 12 50 13 40 1 7 27 13 40 14 30 1 7 28 13 20 14 10 1 Prevalence and characteristics of undiagnosed bipolar disorders in patients with a major depressive episode Charles L. Bowden
16,,, 38, (1990) 17 J Toxicol Sci, 15 (Suppl IV), (1990) 18 Cognitive enhancers ( ), 13, (1990) ,, 120, (1991) 20,
1974 1,, 25, 1385-1391 (1974) 1983 2,, 34, 1451-1454 (1983) 1984 3,, Phencyclidine (PCP),, 4, 133-147 (1984) 1985 4,,,, 11, 132-146 (1985) 1986 5 Phencyclidine Angel Dust, 138, 178-180 (1986) 6, 6, 660-666
1 4 1 13 1 4 6 7 2012 7 27 12 50 13 40 1 7 27 13 40 14 30 1 7 28 13 20 14 10 1 Prevalence and characteristics of undiagnosed bipolar disorders in patients with a major depressive episode Charles L. Bowden
J Kanazawa Med Univ , 2017 要約 :( ) ( ) magnetic resonance imaging (MRI) Hasegawa s dementia scale-revised (HDS-R) 11 7 (WAIS-III) MRI
J Kanazawa Med Univ 42 17 23, 2017 要約 :( ) ( ) 24 9 1.5 magnetic resonance imaging (MRI) Hasegawa s dementia scale-revised (HDS-R) 11 7 (WAIS-III) MRI voxel-based specific regional analysis system for
蜷咲ｧｰ譛ｪ險ｭ螳・3
2011. October vol.606 2 3 2011. October vol.606 4 5 ' 2011. October vol.606 6 7 2011. October vol.606 8 毎 月 18 日 は 9 2011. October vol.606 10 4 4 11 2011. October vol.606 12 39 12 254 13 2011. October
認知症診療ガイドライン2017_100_第1章.indd
1 CQ 1 1 10 ICD 10 /Alzheimer National Institute on Aging Alz heimer s Association workgroup NIA AA 5 DSM 5 ICD 10 1993 1 1 NIA AA 2011 Alzheimer 2 2 DSM 5 2013 neurocognitive disorders dementia major
1 911 9001030 9:00 A B C D E F G H I J K L M 1A0900 1B0900 1C0900 1D0900 1E0900 1F0900 1G0900 1H0900 1I0900 1J0900 1K0900 1L0900 1M0900 9:15 1A0915 1B0915 1C0915 1D0915 1E0915 1F0915 1G0915 1H0915 1I0915
Special IssueDiagnoses and therapeutic agents for age-related diseases Reviews Original Case reports β Medicinal drugs affecting on clinical laboratory blood test results and adverse effects of them
研修コーナー
l l l l l l l Department of Obstetrics and Gynecology, Fukui Medical University, Fukui l l l l l l µ l β β l α l µ µ l l l l Department of Obstetrics and Gynecology, Gifu University School of Medicine,
O1-1 O1-2 O1-3 O1-4 O1-5 O1-6
O1-1 O1-2 O1-3 O1-4 O1-5 O1-6 O1-7 O1-8 O1-9 O1-10 O1-11 O1-12 O1-13 O1-14 O1-15 O1-16 O1-17 O1-18 O1-19 O1-20 O1-21 O1-22 O1-23 O1-24 O1-25 O1-26 O1-27 O1-28 O1-29 O1-30 O1-31 O1-32 O1-33 O1-34 O1-35
障害者職域拡大カリキュラム研究会中間報告書構成案
3 4 5 5 7 7 9 () 9 ()23 34 1 36 47 49 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 ADL QOL 36 37 38 39 40 41 42 43 44 45 46 16 8 () 19 ( ) () 21 () 47 16
<93C195CA D834F E696E6464>
45 I I Diabetes and Heart: Insight by Imaging Juhani Knuuti Turku PET Centre, Turku University Central Hospital II I Development and Application of Beta-Amyloid Imaging Agents Chet A. Mathis Department
若年認知症支援ハンドブック_H19
64 18 18 19 203 50 65 1) - 1 - 18 64 40 64 65 18 3064 10 54 4564 98 35 15 18 2) 45 64 10 6781 3) 1996 10 32 25600 34 10 70008000 4, 5) 10 5) 30 5 2 2) 58 42 2) 2:1 4) - 2 - 1 24, 6) Harvey 3064 185
エンジョイ北スポーツ
2772083130 83 1 2 3 4 5 6 7 8 2 2 2 3 3 4 4 6 7 8 1211 53 /15,171 /509 /670 /13,992 2 83130 http://www.kita-city-taikyo.or.jp 83130 http://www.kita-city-taikyo.or.jp 3 68 35 45 4 83130 http://www.kita-city-taikyo.or.jp
Microsoft PowerPoint UTNP.ppt
Neuropathology Shigeo Murayama 2007.05.21 Department of Neuropathology (Brain Bank) Tokyo Metropolitan Institute of Gerontology Today s Themes A. General consideration Hierarchy of the nervous system Dynamic
診療情報提供書
18 F-AV45( Florbetapir) を用いた脳アミロイドイメージング 柴田俊秀 1 米澤久司 1 高橋智 1 高橋純子 1 工藤雅子 1 小原智子 1 佐々木敏秋 2 寺崎一典 2 世良耕一郎 2 寺山靖夫 1 1 岩手医科大学内科学講座神経内科 老年科分野 020-8505 岩手県盛岡市内丸 19-1 2 岩手医大サイクロトロンセンター 020-0173 岩手県岩手郡滝沢村滝沢字留が森
第５８巻６号／投稿規定・目次・表２・奥付・背
Feature articles 1Why is it that allergic diseases have been increasing? Feature articles 2Space medicine and medicine for the future Review γ ε γ γ γγ α αβ et al et al et al et al et al et al Is nutritional
1 6 1 3 1 4 4 6 11 13 30 14 10 1 6 11 14 10 15 00 1 6 12 13 10 14 00 1 A novel psychotherapeutic intervention for treatment resistant depression and suicidal behaviour at the Life Promotion Clinic: Emotion
TFT 2F 1000 OD ALS SMA 2 TFT 2F 500 OD TFT 2F 300 OD TFT 9F OD CIDP 5 TFT 9F 906 OD
1 11 23 1 TFT 2F 1000 11 10 12 10 AOD1 1 01 06 1 AOD1 1 07 11 2 2 TFT 2F 500 11 10 12 10 AOM1 2 01 04 1 AOM1 2 05 08 2 3 TFT 2F 300 11 10 12 10 OD1 3 01 06 OD1 3 07 11 1 4 TFT 9F 904+905 11 10 12 10 OD1
学位論文内容の要旨 Characteristics of mild cognitive impairment tending to convert into Alzheimer s disease or dementia with Lewy bodies: a follow-up study in
学位論文内容の要旨 Characteristics of mild cognitive impairment tending to convert into Alzheimer s disease or dementia with Lewy bodies: a follow-up study in a memory clinic ( アルツハイマー病やレビー小体型認知症に移行しやすい軽度認知障害の特徴
ｎｓｇ０２－１３／ｋｙ０４５０５９３０１６０００３３２１０
φ φ φ φ κ κ α α μ μ α α μ χ et al Neurosci. Res. Trpv J Physiol μ μ α α α β in vivo β β β β β β β β in vitro β γ μ δ μδ δ δ α θ α θ α In Biomechanics at Micro- and Nanoscale Levels, Volume I W W v W
2016 44 2060 4
27 28217 15:00 16:30 2016 44 2060 4 () 81 099(269)4119 2253 099(238)0168 191 0993(72)4747 34 0996(53)1005 8621 0996(82)2955 998 0995(42)8558 1854 0995(74)1140 170 0997(52)0034 BPSD 2005 85 2 1 () http://www.dcnet.gr.jp/
講習会 Key words : Frontal Assessment Battery FAB Behavioural Assessment of the Dysexecutive Syndrome BADS Trail Making Test Stroop Test
講習会 Key words : 1 2 3 4 1 2 3 4 Frontal Assessment Battery FAB Behavioural Assessment of the Dysexecutive Syndrome BADS Trail Making Test Stroop TestWisconsin Card Sorting Test Tower of Hanoi 1 2 2 I.
β β β β β β
β β β β β β β β β β β β β β β β β θ β α γ et al et al et al β β et al β et al in vivo et al γ et al et al et al et al et al et al Ectopic fat deposition, type 2 diabetes mellitus and cardiovascular diseases
Vol.19 No FTD 3 Pick 2 3 frontal lobe degeneration: FLDPick Pick FLD MND FLD 図 1 3) Frontotemporal lobar degeneration(ftld) 概念の台頭と定着 FTD progre
Frontotemporal lobar degeneration 変遷する病理学的概念と定型的臨床徴候 Frontotemporal lobar degeneration: ever evolving pathological concepts and typical clinical presentations 昭和大学横浜市北部病院内科 / 准教授 ( 神経内科担当 ) * はじめに Frontotemporal
1 1 2 2 3 4 5 5 6 7 8 10 9 10 10 10 11 13 14 15 15 16 17 18 19 21 21 22 22 24 28 38 40 41 41 43 45 46 47 47 47 47 48 50 50 50 50 51 52 54 54 55 56 56 57 57 57 58 58 59 59 59 61 61 61 62 62 62 62 63 63
4 A) (OECD,2005) 78.4 85.3 (WHO,2002) B) 5 A) B) C) 1 7 2
5 2006 9 1 A) 1 2 3 4 B) 1 2 3 4 5 2 A) GDP 7.9 B) 31 25 8 10 1 45 3 31 8 2 70 1 4 A) (OECD,2005) 78.4 85.3 (WHO,2002) B) 5 A) B) C) 1 7 2 1.6 3 31.1 4 2 5 3 4 CT MRI PET 1 30 A) 1 2 6 B) 1 2 3 4 5 3 90.5
発表日 発表時間を変更することはできませんので ご了承ください 発表日ごとに演題番号奇数 偶数の順に各 30 分間の待機時間を設けますので その時間帯はご自身のポスター前で待機し討論を行ってください 待機時間以外は自由にご討論ください (11/24( 金 )17:40 18:10 11/25( 土
001 20281 11 月 24 日 ( 金 ) 16:40~18:10 学会奨励賞候補演題 ( 基礎 ) Tauopathy 培養細胞モデルを用いたTauの凝集 伝播に関わるアミノ酸配列の同定 002 20260 11 月 24 日 ( 金 ) 16:40~18:10 学会奨励賞候補演題 ( 基礎 ) Tau antibody targeting pathological species blocks
同窓会（本間）.indd
76 (4-5): 235 239 (2017) 235 講 演 平成 28 年日本大学医学会秋季学術大会同窓会学術奨励賞受賞講演 -synucleinopathy Ⅰ.α-synucleinopathy? Ⅰ-1.α-synucleinopathy とは -synucleinopathy -synuclein (asyn) 1 Parkinson (Parkinson s disease, PD)
..
A general framework of interventional study in cognitive rehabilitation for the elderly. YOSHIDA Hajime, OOKAWA Ichiro and TUCHIDA Noriaki The present article describes the general framework of our interventional
) 5 Lawton QOL 4 4 QOL Lawton 4) Philadelphia Geriatric Center Affect Rating ScaleARS ARS QOL 5) HDS R
Vol. 12 No. 2 2002 389 397 Λ1 Λ2 16 10 30 1 2 Lawton Philadelphia Geriatric Center Affect Rating ScaleARS Lawton ARS + ARS 6 2 ARS 2 12:00 15:0017:00 11:30 16:00 1 2 ARS 1 2 ARS QOL QOL QOL 1) QOL QOL
兵庫県立大学学報vol.17
THE UNIVERSITY OF HYOGO NEWS 2014 VOL.17 THE UNIVERSITY OF HYOGO NEWS 2014 VOL.17 THE UNIVERSITY OF HYOGO NEWS 2014 VOL.17 THE UNIVERSITY OF HYOGO NEWS 2014 VOL.17 School of Human Science and Environment
1 5 6 2 3 7 8 4 5 9 10 6 7 11 12 8 1 2 3 4 5 6 7 1989 25.0% 19901999 6 2000 15.0% 9 13 1 2 3 4 5 50 2 5180 45.0% 81 35.0%, 5.0% + +, 5.0% +, 1, 5 +, 3 14 10 0% 20% 40% 60% 80% 100% n=20 3 5 2 n=20 55.0%
01_10月号_topics_0927.ai
ADVANCE News 10 2011 October Vol.91 2 3 INTERVIEW 8:00 9:00 10:00 11:00 17:00 18:00 19:00 Schedule 4 8:30 9:00 10:00 12:00 13:00 Schedule 14:00 17:00 18:00 5 9:00 12:00 16:00 Schedule 17:00 9:00 12:00
? diffuse Lewy body disease; DLBD 1996 Neurology dementia with Lewy bodies; DLB % % 20% 2 1 3
? 976 984 diffuse Lewy body disease; DLBD 996 Neurology dementia with Lewy bodies; DLB 203 4.3% 0 2000 0 8% 20% 2 3 90 QOL BPSD 204 BPSD NMDA 4 5 CONTENTS 5 40 part 2 23 3 7 4 9 3 42 2 43 345 4 46 5 47
Stabilometry-Significance of Locus Length per Unit Area (L/A) in Patients with Equilibrium Disturbances- Tsuyoshi Okawa, Takashi Tokita, Yasunari Shib
Stabilometry-Significance of Locus Length per Unit Area (L/A) in Patients with Equilibrium Disturbances- Tsuyoshi Okawa, Takashi Tokita, Yasunari Shibata Tetsuya Ogawa, Hideo Miyata 1) Department of Otolaryngology,
untitled
The University of Tokyo Magazine t a n s e i 23 2010/01!? ] 2 The University of Tokyo Magazine t a n s e i 23 2010/01 1920 23 35 contents p.03-29 [] p.30-31 []!? p.32-33 [] p.34-35 [] 3 JR 1949 1961 1967
臨床神経学雑誌第49巻第5号
Alzheimers β Table1 NeuropathologicalclassificationofFTLD 1.Tauopathy(withassociatedneuronlossandgliosis)andinsolubletauwithapredominanceof3Rtau,themostlikely diagnosesare: FTLD withpickbodies a) FTLD
Dynamic Neuropathology of age- associated cognitive decline 村山繁雄 * 齊藤祐子 * 高齢者の認知障害は 個人においても集団においても連続的である これらの正確な解明には 臨床的縦断研究と 神経病理学的後方視的研究と組み合わせる以外ない
Dynamic Neuropathology of age- associated cognitive decline 村山繁雄 * 齊藤祐子 * 高齢者の認知障害は 個人においても集団においても連続的である これらの正確な解明には 臨床的縦断研究と 神経病理学的後方視的研究と組み合わせる以外ない 老化に伴う認知機能の動的神経病理 ( 臨床 画像 病理連関 ) を述べるにあたり 高齢者ブレインバンク内に蓄積された
Microsoft Word - 21C04 神内2.docx
18 F-AV-45(Florbetapir F 18) を用いた認知症における 脳アミロイドイメージング 柴田俊秀 1 米澤久司 1 高橋純子 1 工藤雅子 1 小原智子 1 鈴木真紗子 1 石塚直樹 1 藤澤豊 1 佐々木敏秋 2 寺崎一典 2 世良耕一郎 2 寺山靖夫 1 1 岩手医科大学内科学講座神経内科 老年科分野 020-8505 岩手県盛岡市内丸 19-1 2 岩手医科大学サイクロトロンセンター
untitled
5 K 5 3 HP http://www.mhlw.go.jp/bunya/shakaihosho/iryouseido01/taikou03.html 2004 1 2 1 http://www.dm-net.co.jp/calendar/2007/06/005835.php 6 85cm 100cm 2 90cm 2 TG 150mg/dl HDLHDL-C 40mg/dl 130mmHg 85mmHg
15ol
2010. October vol.594 2 3 2010. October vol.594 4 (営業時間:10 時~18 時) (営業時間:11 時~22 時) (営業時間:9時~18 時) (開館時間:9時~21 時30 分) 5 6 2010. October vol.594 ' 4 4 4 7 8 2010. October vol.594 9 11 12 2010. October vol.594
2007 2 3 4 6 15 15 16 18 20 21 22 23 57 59 2 2 42% 2007 2006 2005 2004 2003 200 160 120 80 40 0 118.1 116.1 129.6 137.7 111.7 2006 2005 2004 2003 200 160 120 80 40 0 154.1 156.9 178.3 188.9 2007 193.4
2018表紙.indd
8 57 60 3 11 2018 2 2018 2 3 1 ISBN 2 230 3 http:// www.unp.or.jp 1 412 2,000 320 2,000 352 1,600 268 1,800 1982 86 195 21 1987 978-4-930689-67-2 SDI 1989 978-4-8158-0116-8 1983 978-4-930689-08-5 1984
U50068.indd
1 氏 名 たか髙 の野 まさ雅 つぐ嗣 学位の種類学位記番号学位授与の日付学位授与の要件 博士 ( 医学 ) 甲第 645 号平成 26 年 9 月 30 日学位規則第 4 条第 1 項 ( 内科学 ( 神経 )) 学位論文題目 Effects of memantine on event-related potentials in Alzheimer s disease under donepezil
研修コーナー
l l l l l l l l l l l α α β l µ l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
Soundcell Method（SCM）による高齢者の認知機能評価の可能性
Soundcell Method SCM Soundcell Soundcell Method SCM Soundcell Soundcell SCM SCM SCM SCM MMSE TMT-A TMT-BSCM SCM SCM SCM MMSE MMSE SCM SCM Soundcell Soundcell Method Soundcell Soundcell Soundcell Soundcell
【日本放射線技術学会北海道部会メールマガジン 125号 2014/05/30 】
125 vol.125 2014/05/30 reader 42 Ambitious 2014 - make the next frontier, make the new future - [ ] 2014 10 9 ( ) 11 ( ) [ ] 003-0006 6 1 1-1 TEL 011-817-1010 [ ] ( ) ( ) [ ] ( ) [ ] 26 4 25 ( ) 6 1 (
Isotope News 2017年10月号 No.753
Ishioka Noriko ₁ はじめに RI RI RI RI ₂ 悪性褐色細胞腫と治療の現状 3,000 90 I meta- Iiodo-benzylguanidine I-MIBG 1 ₃ α 線の標的アイソトープ治療 2016 6 223 RaCl2 223 Ra 223 Ra 14 表 1 α 線と β 線の違い -decay (42%) Eα = 5.9 MeV At 7.2 h EC
NIHSS score p NIHSS score p149 4 p g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml
NIHSS score14 1 400 1 p149 1 25 20 NIHSS score14 15 10 5 2 p149 4 p151 0 0.8 g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml 1 2 148 149 3 2 3 A B C 4 D 2 A B C A C 1 Ogata T et al J Neurol Sci 272 83 86 2008
American psychiatric association: APA, 2000 Diagnostic and Statistical Manual- -TR DSM- -TR world health organization: WHO, 199
2020 4 1 2050 3 1 65 1 American psychiatric association: APA, 2000 Diagnostic and Statistical Manual- -TR DSM- -TR world health organization: WHO, 1992 International Classification of Diseases-10 ICD-10
業績集2011.8より.xlsx
2011.4-2012.3 2011 4 pp.80-86 2011 4 pp.100-106 2011 4 pp.171-185 2011 7 pp26-29 2011 8 2011 8 pp56-61 2011 11 pp117-127 2011 11 pp.245-252 2011 11 2011 12 1 12 13 Osawa Y,Oguma Y Effects of whole-body
ren
51 * 1 1 IT 24 2010 NHK 2010 7.14 1960 1.08 OECD 2 5 1 2011 4 World Association of Sleep Medicine WASM 3 18 World Sleep Day 2011 11 30 no. 22730552 9 3 1 4,000 5,000 1998 4 4.4 3.3 Matsuda, 2011 Cognitive